2 Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2013, 34(28): 2159-2219.
[3]
3 James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5): 507-520.
[4]
4 Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society[J]. J Renin Angiotensin Aldosterone Syst, 2006, 7(2): 61-63.
7 Panjabi S, Lacey M, Bancroft T, et al. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients[J]. J Am Soc Hypertens, 2013, 7(1): 46-60.
[8]
8 Baser O, Andrews LM, Wang L, et al. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy[J]. J Med Econ, 2011, 14(5): 576-583.
[9]
9 Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis[J]. Am J Med, 2007, 120(8): 713-719.
[10]
10 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)[J]. JAMA, 2002, 288(23): 2981-2997.
[11]
11 Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group[J]. JAMA, 1999, 281(21): 2005-2012.
[12]
12 Hovater MB, Jaimes EA. Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination[J]. Integr Blood Press Control, 2013, 6: 59-67.
[13]
13 Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial[J]. Clin Ther, 2005, 27(7): 1013-1021.
[14]
14 Zhu DL, Gao PJ, Liu SW, et al. Efficacy and tolerability of a single-pill combination of telmisartan/hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension: a subgroup analysis of a randomized, double-blind, active-controlled trial[J]. Chin Med J, 2013, 126(21): 4072-4077.
[15]
15 Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study[J]. Clin Ther, 2005, 27(5): 578-587.
[16]
16 Zhu D, Gao P, Yagi N, et al. Efficacy and tolerability of telmisartan plus amlodipine in Asian patients not adequately controlled on either monotherapy or on low-dose combination therapy[J]. Int J Hypertens, 2014: 475480.
[17]
17 Neldam S, Edwards C, Lang M, et al. Long-term tolerability and efficacy of single-pill combinations of telmisartan 40-80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 studies[J]. Curr Ther Res Clin Exp, 2012, 73(1/2): 65-84.
[18]
18 Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials[J]. Clin Ther, 2005, 27(11): 1795-1805.
[19]
19 Neldam S, Lang M, Jones R, et al. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study[J]. J Clin Hypertens (Greenwich), 2011, 13(7): 459-466.
[20]
20 Zhu DL, Bays H, Gao P, et al. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial[J]. Clin Ther, 2012, 34(7): 1613-1624.
